Table 4 Treatment of patients with COVID-19
Total (n = 91) | Severe (30, 33.0%) | Mild (61, 67.0%) | P value | |
|---|---|---|---|---|
glucocorticoid | 79/91 (86.8%) | 25/30 (83.3%) | 54/61 (88.5%) | 0.399 |
antiviral therapy | 81/91 (89.0%) | 24/30 (80.0%) | 57/61 (93.4%) | 0.061 |
oseltamivir | 24/91 (26.4%) | 6/30 (20.0%) | 18/61 (29.5%) | 0.240 |
lopinavir/ritonavir | 64/91 (60.3%) | 16/30 (53.3%) | 48/61 (78.7%) | 0.013 |
umifenovir | 53/91 (58.2%) | 22/30 (73.3%) | 31/61 (50.8%) | 0.033 |
antibacterial therapy | 90/91 (98.9%) | 30/30 (100.0%) | 60/61 (98.4%) | 0.670 |
cephalosporin | 27/91 (29.7%) | 12/30 (40.0%) | 15/61 (24.6%) | 0.103 |
fluoroquinolones | 84/91 (92.3%) | 27/30 (90.0%) | 57/61 (93.4%) | 0.421 |
carbapenems | 2/91 (2.2%) | 2/30 (6.7%) | 0 (0) | 0.059 |
immunoglobulin | 35/91 (38.5%) | 16/30 (53.3%) | 19/61 (31.2%) | 0.035 |
oxygen therapy | 29/91 (31.9%) | 17/30 (56.7%) | 12/61 (19.7%) | 0.001 |
mechanical ventilation | 5/91 (5.5%) | 5/30 (16.7%) | 0 (0) | 0.003 |
CRRT | 3/91 (3.3%) | 3/30 (10.0%) | 0 (0) | 0.033 |